These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 26769867)

  • 21. The radioactive drug research committee: Background and retrospective study of reported research data (1975-2004).
    Suleiman OH; Fejka R; Houn F; Walsh M
    J Nucl Med; 2006 Jul; 47(7):1220-6. PubMed ID: 16818959
    [TBL] [Abstract][Full Text] [Related]  

  • 22. CGMP for PET drugs: important steps to take now.
    Vanbrocklin H; Schwarz S
    J Nucl Med; 2010 Dec; 51(12):17N. PubMed ID: 21098789
    [No Abstract]   [Full Text] [Related]  

  • 23. What is now current good manufacturing practice for PET drugs?
    Harolds J
    Clin Nucl Med; 2010 May; 35(5):329. PubMed ID: 20395704
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Draft guidance for industry on developing medical imaging drugs and biologics; availability--FDA. Availability of guidance.
    Fed Regist; 1998 Oct; 63(198):55067-9. PubMed ID: 10185833
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Receptor targeting agents for imaging inflammation/infection: where are we now?
    Signore A; Chianelli M; D'Alessandria C; Annovazzi A
    Q J Nucl Med Mol Imaging; 2006 Sep; 50(3):236-42. PubMed ID: 16868537
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Medical Imaging & Technology Alliance conference on research endpoints appropriate for medicare coverage of new PET radiopharmaceuticals.
    Hillman BJ; Frank RA; Abraham BC
    J Am Coll Radiol; 2013 Sep; 10(9):689-94. PubMed ID: 23916799
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Development of radioimmunotherapeutic and diagnostic antibodies: an inside-out view.
    Boswell CA; Brechbiel MW
    Nucl Med Biol; 2007 Oct; 34(7):757-78. PubMed ID: 17921028
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Current good manufacturing practice for positron emission tomography drugs.
    Food and Drug Administration, HHS
    Fed Regist; 2009 Dec; 74(236):65409-36. PubMed ID: 20169678
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Imaging as a tool in drug development.
    Strack T
    Drugs Today (Barc); 2007 Oct; 43(10):725-36. PubMed ID: 17987225
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Translating a radiolabeled imaging agent to the clinic.
    Griffiths GL; Vasquez C; Escorcia F; Clanton J; Lindenberg L; Mena E; Choyke PL
    Adv Drug Deliv Rev; 2022 Feb; 181():114086. PubMed ID: 34942275
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The radioprotection management of a PET department with a cyclotron and radiopharmacy laboratory, in accordance with Italian legislation.
    Russo AA; Ferrari P; Casale M; Delia R
    Radiat Prot Dosimetry; 2011 Sep; 147(1-2):240-6. PubMed ID: 22039292
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Can evaluation of targeted therapy in oncology be improved by means of 18F-FLT?
    De Saint-Hubert M; Brepoels L; Mottaghy FM
    J Nucl Med; 2010 Oct; 51(10):1499-500. PubMed ID: 20847167
    [No Abstract]   [Full Text] [Related]  

  • 33. Molecular imaging and personalized medicine: an uncertain future.
    Nunn AD
    Cancer Biother Radiopharm; 2007 Dec; 22(6):722-39. PubMed ID: 18158763
    [TBL] [Abstract][Full Text] [Related]  

  • 34. PET/Computed Tomography Using New Radiopharmaceuticals in Targeted Therapy.
    Sharma P; Kumar R; Alavi A
    PET Clin; 2015 Oct; 10(4):495-505. PubMed ID: 26384596
    [TBL] [Abstract][Full Text] [Related]  

  • 35. (68)Ga-labeled DOTA-peptides and (68)Ga-labeled radiopharmaceuticals for positron emission tomography: current status of research, clinical applications, and future perspectives.
    Breeman WA; de Blois E; Sze Chan H; Konijnenberg M; Kwekkeboom DJ; Krenning EP
    Semin Nucl Med; 2011 Jul; 41(4):314-21. PubMed ID: 21624565
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Food and Drug Administration process for development and approval of drugs and radiopharmaceuticals: treatments in urologic oncology.
    Ning YM; Maher VE
    Urol Oncol; 2015 Mar; 33(3):137-42. PubMed ID: 25613202
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma.
    Lencioni R; Llovet JM
    Semin Liver Dis; 2010 Feb; 30(1):52-60. PubMed ID: 20175033
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A broad overview of positron emission tomography radiopharmaceuticals and clinical applications: what is new?
    Vallabhajosula S; Solnes L; Vallabhajosula B
    Semin Nucl Med; 2011 Jul; 41(4):246-64. PubMed ID: 21624560
    [TBL] [Abstract][Full Text] [Related]  

  • 39. FDG positron emission tomography in pancreatic cancer.
    Tecnologica MAP Suppl; 2000 Jan; ():14-6. PubMed ID: 10848118
    [No Abstract]   [Full Text] [Related]  

  • 40. FDG positron emission tomography in melanoma.
    Tecnologica MAP Suppl; 2000 Jan; ():11-3. PubMed ID: 10848117
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.